FDA Cracks Down on Telehealth Companies Over Misleading GLP-1 Marketing
The U.S. Food and Drug Administration (FDA) is intensifying its scrutiny of the rapidly expanding telehealth sector, issuing 30 warning letters to companies accused of making false or misleading claims regarding compounded versions of glucagon-like peptide-1 (GLP-1) medications. This action, announced on March 3, 2026, signals a broader effort to protect consumers from potentially unsafe or ineffective treatments marketed directly to them, particularly through online channels. The agency’s move comes as demand for GLP-1s, originally developed for managing type 2 diabetes, has surged due to their weight-loss effects, leading to supply challenges and a rise in compounded alternatives.
“It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action,” stated FDA Commissioner Marty Makary, M.D., M.P.H. In a press release. “Compounded drugs can be essential for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA’s approval process.” This latest action builds on a crackdown initiated in September 2025, targeting deceptive direct-to-consumer pharmaceutical advertising. Over the past six months, the FDA has reportedly sent thousands of warning letters, exceeding the total issued over the entire previous decade, demonstrating a significant escalation in enforcement efforts.
What are Compounded Drugs and Why the Concern?
Compounded drugs are created by licensed pharmacies when an FDA-approved drug is not commercially available in the strength, dosage form, or combination needed by a patient. According to the FDA, compounding can be essential for addressing drug shortages or tailoring medications to individual patient needs. However, compounded drugs are not FDA-approved. This critical distinction means the agency does not evaluate their safety, effectiveness, or quality before they reach patients. Unlike generic drugs, which undergo rigorous FDA review, compounded medications operate outside of that regulatory framework.
The primary violations identified in the recent warning letters centered around two key issues. First, several telehealth companies were found to be making claims that implied their compounded GLP-1 products were equivalent to FDA-approved versions, such as Ozempic, Wegovy, or Mounjaro. Second, the FDA noted instances where companies were obscuring the source of their drugs by branding them with their own names or trademarks without clearly disclosing that they were compounded medications. This practice, the agency argues, creates a misleading impression that the telehealth firm is the manufacturer, rather than a distributor of a customized product.
GLP-1s: Rising Demand and the Appeal of Compounding
GLP-1 receptor agonists are a class of drugs initially designed to help manage type 2 diabetes by improving insulin secretion and lowering blood sugar levels. However, these medications have gained widespread attention for their significant weight-loss effects. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become increasingly popular, leading to intermittent supply shortages. Reuters reported in October 2023 that supply issues with Ozempic were ongoing, highlighting the challenges in meeting the growing demand.
The shortages and high cost of branded GLP-1s have fueled the demand for compounded versions, which are often marketed at a lower price point. Telehealth companies have capitalized on this trend, offering convenient access to compounded medications through online consultations and prescriptions. However, the FDA warns that the lack of rigorous oversight in compounding pharmacies raises concerns about the quality and safety of these products. Potential risks include inaccurate dosages, contamination, and the utilize of substandard ingredients.
FDA’s Increased Enforcement and Future Actions
The FDA’s recent actions represent a significant escalation in its efforts to regulate the telehealth industry and protect consumers from misleading pharmaceutical marketing. The agency’s crackdown began in September 2025, and the issuance of 30 warning letters in early March 2026 demonstrates a sustained commitment to enforcement. The FDA has the authority to capture further action against companies that fail to comply with its regulations, including issuing fines, seeking injunctions, and pursuing criminal charges.
The agency is also working to educate consumers about the risks associated with compounded drugs and the importance of verifying the legitimacy of telehealth providers. A consumer update published by the FDA warns against purchasing weight-loss drugs from unauthorized sources and emphasizes the importance of consulting with a licensed healthcare professional.
What This Means for Patients
For patients considering GLP-1 therapy, whether for diabetes management or weight loss, the FDA’s warning underscores the importance of caution and informed decision-making. Individuals should only obtain these medications from licensed pharmacies with valid prescriptions from qualified healthcare providers. It is crucial to discuss the risks and benefits of both FDA-approved and compounded GLP-1s with a doctor before starting treatment.
Patients who have obtained compounded GLP-1s from telehealth companies should be aware of the potential risks and report any adverse effects to their healthcare provider and the FDA’s MedWatch program. The FDA’s MedWatch website provides information on how to report drug-related problems.
Looking Ahead
The FDA’s increased scrutiny of telehealth companies and compounded medications is likely to continue. The agency is expected to release further guidance on the regulation of compounding pharmacies and the marketing of pharmaceutical products online. The ongoing debate over drug shortages, access to affordable medications, and the role of telehealth in healthcare delivery will undoubtedly shape the future of this evolving landscape.
The FDA has not announced a specific date for further action, but agency officials have indicated that they will continue to monitor the telehealth industry closely and take enforcement action as needed. Consumers are encouraged to stay informed about the latest developments and to exercise caution when seeking healthcare services and medications online.
Key Takeaways:
- The FDA issued 30 warning letters to telehealth companies for misleading marketing of compounded GLP-1s.
- Compounded drugs are not FDA-approved and lack the same safety and quality assurances as FDA-approved medications.
- Patients should only obtain GLP-1s from licensed pharmacies with valid prescriptions.
- The FDA is increasing its enforcement efforts to protect consumers from deceptive pharmaceutical marketing practices.
Have you or someone you know been affected by misleading marketing of compounded medications? Share your experiences and thoughts in the comments below. Please also share this article to help raise awareness about the importance of safe and responsible healthcare practices.